Filing to list shares on the NASDAQ under the symbol ADAP, Adaptimmune has unveiled plans for a $150 million IPO. The clinical stage biopharm focuses its research and development on T-cell receptor-based cancer immunotherapies. Proceeds from the offering will be used in part to accelerate the clinical development of one of the company's drug candidates through Phase 1/2 clinical trials. Adaptimmune raised a Series A financing in September, bringing in $104 million at a valuation of $211 million. Backers include New Enterprise Associates (16.6% pre-IPO stake) and OrbiMed Advisors (7.1%).